These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34379251)

  • 1. Surgical Axillary Staging Before Neoadjuvant Chemotherapy: Who Gets It and Why We Should Avoid It.
    Iles K; Strassle PD; Agala CB; Button J; Downs-Canner S
    Ann Surg Oncol; 2021 Oct; 28(10):5788-5797. PubMed ID: 34379251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
    Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Damin AP; Zancan M; Melo MP; Biazus JV
    Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
    Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?
    Cortina CS; Lloren JI; Rogers C; Johnson MK; Cobb AN; Huang CC; Kong AL; Singh P; Teshome M
    Ann Surg Oncol; 2024 May; 31(5):3128-3140. PubMed ID: 38270828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
    Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
    Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management.
    Relation T; Obeng-Gyasi S; Bhattacharyya O; Li Y; Eskander MF; Tsung A; Oppong BA
    Ann Surg Oncol; 2021 Oct; 28(11):6489-6497. PubMed ID: 33586065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
    Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
    Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower lymph node yield in axillary lymph node dissection specimens in breast cancer patients receiving neoadjuvant chemotherapy: Quality concern or treatment effect?
    Ozao-Choy J; Moazzez A; Dauphine C
    Breast J; 2021 Dec; 27(12):851-856. PubMed ID: 34877726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Breast Cancer Pretreatment Nodal Burden and Disease Subtype on Axillary Surgical Management.
    Ng S; Sabel MS; Hughes TM; Chang AE; Dossett LA; Jeruss JS
    J Surg Res; 2021 May; 261():67-73. PubMed ID: 33421795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.
    Montagna G; Mamtani A; Knezevic A; Brogi E; Barrio AV; Morrow M
    Ann Surg Oncol; 2020 Oct; 27(11):4515-4522. PubMed ID: 32488513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.